Track AVEO Pharmaceuticals's common stock ($35M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
As of the most recent data (September 2022), AVEO shows a common stock of $35M. That compares with $34M in the prior-year period — up 0.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, AVEO's common stock is now $35M (was $34M) — a 0.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether AVEO Pharmaceuticals is outperforming or lagging.
Tracking AVEO's common stock over time shows whether AVEO Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $35M That compares with $34M in the prior-year period — up 0.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this common stock page, Stockcircle has AVEO Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $35M) with ownership activity and broader fundamentals.
AVEO Pharmaceuticals's common stock is $35M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.